Part 14 - Targeting EGFR in HNSCC - Dr. K. Govind Babu, Bengaluru

preview_player
Показать описание
ISMPOCON Day 1 - 6 Nov 2020
  1. MICE IDEAS
  2. Oncology
  3. Lung Cancer
Рекомендации по теме
Part 14 - 0:13:03

Part 14 - Targeting EGFR in HNSCC - Dr. K. Govind Babu, Bengaluru

Understanding NSCLC Treatment 0:05:03

Understanding NSCLC Treatment When You Have an EGFR Mutation

What is an 0:02:21

What is an EGFR mutation in lung cancer?

Dr Herbst on 0:01:16

Dr Herbst on the Evolution of EGFR Inhibition in Lung Cancer

Challenges in Targeting 0:11:51

Challenges in Targeting the EGFR Receptor in Glioblastoma

Christi - What 0:04:38

Christi - What has your treatment experience been for your EGFR-positive lung cancer?

Multimodal Management of 0:41:23

Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings

Christi - How 0:02:28

Christi - How did you find out you had EGFR-positive lung cancer?

EGFR TKI Resistance: 0:08:00

EGFR TKI Resistance: Targeting MET Amplification

GFR under 15-- 0:00:57

GFR under 15-- but NUTRITION matters even more now!

CRSF 7th Masterclass 0:18:40

CRSF 7th Masterclass | Hidden EGFR Threats & Role of Amivantamab by Dr. Anshul Gupta | Day 3

ESMO Clinical Practice 0:02:47

ESMO Clinical Practice Guidelines: beyond EGFR and ALK

Refining Biomarker Testing 0:59:37

Refining Biomarker Testing and Targeted Treatment of NSCLC With EGFR Mutations

EGFR: The Challenge 0:44:03

EGFR: The Challenge of Primary and Secondary Resistance

How do doctors 0:03:41

How do doctors treat lung cancer with EGFR mutations?

Navigating Rapid Changes 0:59:03

Navigating Rapid Changes in First- and Later-Line Treatment of EGFR-Mutated NSCLC

Evaluating the Role 0:01:14

Evaluating the Role of EGFR Mutations in the Treatment of Advanced NSCLC

Targeted treatment with 0:20:24

Targeted treatment with EGFR TKIs: Front line options

Glioblastoma/Grade 4 Astrocytoma: 0:31:39

Glioblastoma/Grade 4 Astrocytoma: Personalized Medicine & Targeted Therapy

The Molecular Tumor 0:45:12

The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI Resistance

Understanding EGFR Resistance 0:02:02

Understanding EGFR Resistance in Patients With MET-Amplified NSCLC

2021 West Oncology 0:20:34

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2

Mechanisms of Resistance 0:03:48

Mechanisms of Resistance to Upfront EGFR-Targeted Therapy

IMMUNOHISTOCHEMISTRY: EPIDERMAL GROWTH 0:03:07

IMMUNOHISTOCHEMISTRY: EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)